... 20 and 10 years, respec-tively, and continue as valuable agents for treatment of Gram-negative infections. However, they have a narrow therapeuticwindow and the need for low-dose therapy to ... carbapenem dosing and adverse event risks,pharmacodynamic-based dosing, and costs. It focuses onimipenem, meropenem, and doripenem, as they are morecommonly used as empiric treatments for seriously ... intra-abdominal, urinary tract, and skin and skin structure infections. They are prescribed byhospitalists, surgeons, intensivists, wound care specialists, and infectious disease physicians...